Filgrastim This page contains brief information about filgrastim and a collection of links to more information about the use of this drug, related news and research results, and ongoing clinical trials.
US Brand Name(s): | | Neupogen | | | FDA Approved: | | Yes |
Filgrastim is approved by the Food and Drug Administration (FDA) to prevent and treat neutropenia caused by some types of chemotherapy. It is used in patients who are having the following types of treatment: Filgrastim is also used in patients who are going to have chemotherapy and a stem cell transplant. Filgrastim moves stem cells from the bone marrow into the bloodstream, so they can be collected, stored, and given back to the patient. Filgrastim is also used to treat patients with the following chronic forms of neutropenia:
Filgrastim is a type of granulocyte colony-stimulating factor (G-CSF). Filgrastim is being studied in the treatment of other types of cancer. Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trial Results: Granulocyte Colony-Stimulating Factor (G-CSF) Prevents Common Chemotherapy Complication - Important clinical trial results for this drug, background information, and how the trial was done.
Biological Therapies for Cancer: Questions and Answers - Information about the use of this drug to treat cancer.
Hematopoietic Drugs During Chemotherapy May Raise Leukemia Risk - Information about the use of this drug to treat cancer.
Information from the National Library of Medicine (NLM)
MedlinePlus Information on Filgrastim - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied. Clinical TrialsClinical Trials for Filgrastim - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top |